Charles River Laboratories (CRL)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$228.72-1.17%
Close 2026-07-07 · 1-day change
Reading CRL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CRL free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading CRL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CRL free→QuarterlyIQ Insights · CRL
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $228.72. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $229 CRL trades at 30× p/e, below its 35× p/e peer median, but our blended $201 fair value sits below the price. It's a high-confidence read. Analysts target $192–$250. Not investment advice.
$192.00 – $250.00 (median $219.50) · 10 analysts · as of 2026-07-01
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 64% over what the business is worth with no growth; closing that gap needs roughly — years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $8.92/sh owner earnings.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $219.50 | — | — | Analyst | high |
| dcf fcfe | 12M | $163.27 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $139.64 | — | — | Hist. CAGR | high |
| graham number | 12M | $101.72 | — | — | TTM | high |
| Mgmt guidance | 12M | $386.78 | 35.3 | 10.95 | Mgmt | high |
| Peer EV/EBITDA | 12M | $208.84 | 15.5 | 16.77 | TTM | high |
| Peer P/FCF | 12M | $252.06 | 31.5 | 7.99 | TTM | high |
| Peer P/E | 12M | $269.87 | 35.3 | 7.64 | TTM | high |
| Peer P/S | 12M | $299.74 | 3.6 | 82.27 | TTM | high |
| PEG | 12M | $440.65 | 57.7 | 7.64 | TTM | high |
| residual income | 12M | $66.04 | — | — | TTM | high |
| Own P/E history | 12M | $181.02 | 23.7 | 7.64 | TTM | high |
| triangulated | 12M | $280.20 | 35.3 | 7.93 | Triangulated | high |
| Mgmt guidance | 3Y | $1016.88 | 35.3 | 28.79 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $358.32 | 31.5 | 11.36 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $509.58 | 35.3 | 14.43 | Analyst | medium |
| Peer P/S | 3Y | $404.42 | 3.6 | 111.00 | guidance | medium |
| PEG | 3Y | $832.08 | 57.7 | 14.43 | Analyst | medium |
| Own P/E history | 3Y | $341.82 | 23.7 | 14.43 | Analyst | medium |
| Mgmt guidance | 5Y | $1937.02 | 35.3 | 54.84 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $453.03 | 31.5 | 14.37 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $622.21 | 35.3 | 17.61 | Analyst | high |
| Peer P/S | 5Y | $493.80 | 3.6 | 135.53 | guidance | high |
| PEG | 5Y | $1015.99 | 57.7 | 17.61 | Analyst | high |
| Own P/E history | 5Y | $417.38 | 23.7 | 17.61 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.